(Q37772510)

22 August 2017

1 reference

title

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies (English)

1 reference

22 August 2017

0 references

0 references

0 references

1 reference

1 reference

2

Gerald F Watts

1 reference

22 August 2017

Dick C Chan

1

1 reference

PubMed ID

20629587

22 August 2017

language of work or name

English

0 references

publication date

14 July 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

1 reference

22 August 2017

12

1 reference

22 August 2017

1

1 reference

22 August 2017

13-30

1 reference

Obesity, Metabolic Syndrome, and Cardiovascular Disease

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Metabolic syndrome: focus on dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Insulin resistance and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

The insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Small, dense low-density-lipoproteins and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Metabolic and lifestyle determinants of postprandial lipemia differ from those of fasting triglycerides: The Atherosclerosis Risk In Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Oxidation of chylomicron remnants and vascular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

The role of stable isotopes in the investigation of plasma lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Use of stable isotopically labeled tracers for studies of metabolic kinetics: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Kinetics of triglyceride rich lipoproteins: chylomicrons and very low density lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

HDL metabolism in hypertriglyceridemic states: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

New insight into the pathophysiology of lipid abnormalities in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Weight reduction increases adipose tissue lipoprotein lipase responsiveness in obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Mechanism of intestinal lipoprotein overproduction in insulin resistant humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

The effects of low-fat, high-carbohydrate diets on plasma lipoproteins, weight loss, and heart disease risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Lipoprotein subfractions of runners and sedentary men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Physical activity and the prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

A single bout of whole-body resistance exercise augments basal VLDL-triacylglycerol removal from plasma in healthy untrained men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of the amount and intensity of exercise on plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Comparative effects of lipid-lowering therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Comparison of statins in hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Narrative review: statin-related myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of niacin on glucose control in patients with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Omega-3 polyunsaturated fatty acid regulation of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Responses of LDL and HDL particle size and distribution to omega-3 fatty acid supplementation and aerobic exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Non-adherence to statin therapy: a major challenge for preventive cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

Trajectories of Entering the Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.502529

10.1517/14656566.2010.502529

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20629587